Trial · NCT00024258
Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors
NCT00024258, Phase 2, Completed, Memorial Sloan Kettering Cancer Center; results first posted 2015-11-25
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors. Trials, record NCT00024258. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00024258
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors
- NCT number
- NCT00024258
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 22 participants, actual
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer, Liver Cancer, Neuroblastoma, Ovarian Cancer, Retinoblastoma, Sarcoma
- Interventions
- arsenic trioxide
- First posted
- 2003-01-27
- Last updated
- 2015-11-25
- Results first posted
- 2015-11-25
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Response Rate After Every 3 Courses During Treatment and Then Every 2-3 Months for 1 Year After Completion of Treatment | 1 year |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Response Rate After Every 3 Courses During Treatment and Then Every 2-3 Months for 1 Year After Completion of Treatment | 1 year | participants | NUMBER |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Response Rate After Every 3 Courses During Treatment and Then Every 2-3 Months for 1 Year After Completion of Treatment | Arsenic Trioxide | Progression of Disease | 16 | participants | |
| Response Rate After Every 3 Courses During Treatment and Then Every 2-3 Months for 1 Year After Completion of Treatment | Arsenic Trioxide | Stable Disease | 5 | participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Arsenic Trioxide | 22 | |
| Overall Study | COMPLETED | Arsenic Trioxide | 13 | |
| Overall Study | NOT COMPLETED | Arsenic Trioxide | 9 |
Source ClinicalTrials.gov
Adverse events52
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anorexia | Metabolism and nutrition disorders | Arsenic Trioxide | 2 | 22 | 2 |
| other | Blood bilirubin increased | Investigations | Arsenic Trioxide | 1 | 22 | 15 |
| other | Bone pain | Musculoskeletal and connective tissue disorders | Arsenic Trioxide | 4 | 22 | 4 |
| other | Bruising | Injury, poisoning and procedural complications | Arsenic Trioxide | 1 | 22 | 1 |
| other | Conjunctivitis | Eye disorders | Arsenic Trioxide | 1 | 22 | 1 |
| other | Constipation | Gastrointestinal disorders | Arsenic Trioxide | 3 | 22 | 3 |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Arsenic Trioxide | 3 | 22 | 4 |
| other | Dry Eye | Eye disorders | Arsenic Trioxide | 1 | 22 | 1 |
| other | Dyspnea | Respiratory, thoracic and mediastinal disorders | Arsenic Trioxide | 2 | 22 | 2 |
| other | Edema | General disorders | Arsenic Trioxide | 3 | 22 | 3 |
1 to 10 of 52Source ClinicalTrials.gov
See all 52 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Arsenic Trioxide | ||
| Total, other adverse events | Arsenic Trioxide | 14 | 22 |
| Total, serious adverse events | Arsenic Trioxide | 12 | 22 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| P30CA008748 | Cancer Center Support Grant | Rudin, Charles M. | SLOAN-KETTERING INST CAN RESEARCH | NATIONAL CANCER INSTITUTE | 1985 to 2026 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00024258
GET https://conductscience.org/api/trials/v1/NCT00024258/events?page=2